


Ruxolitinib (S enantiomer)

Cat. No.:	HY-50856A		
CAS No.:	941685-37-6		
Molecular Formula:	C ₁₇ H ₁₈ N ₆		
Molecular Weight:	306.37		
Target:	JAK		
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (326.40 mM)
 1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.2640 mL	16.3201 mL	32.6403 mL
	5 mM		0.6528 mL	3.2640 mL	6.5281 mL
	10 mM		0.3264 mL	1.6320 mL	3.2640 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is a JAK inhibitor^[1]

IC₅₀ & Target

JAK

CUSTOMER VALIDATION

- Commun Biol. 2021 Jun 2;4(1):654.
- Research Square Preprint. 2020 Dec.
- bioRxiv. 2020 Oct 5;2020.10.04.325415.
- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wayne Rothbaum. Methods of treating myeloproliferative neoplasms. WO2019224803A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA